GO:0008013 beta-catenin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008013 beta-catenin binding is a molecular function defined as binding to a catenin beta subunit, and it is central to Wnt signal transduction.
• Beta-catenin binding partners include TCF/LEF transcription factors, FoxO1, ESE1, BAG2, SAMD4B, and components of biomolecular condensates.
• The interaction between beta-catenin and TCF1 versus FoxO1 can determine whether renal tubular cells drive fibrosis or maintain homeostasis.
• Beta-catenin cleavage and condensate formation are mechanisms that regulate its transcriptional activity and target gene activation.
• Dysregulated beta-catenin binding is implicated in cancers such as cholangiocarcinoma and liver tumors, as well as chronic kidney fibrosis.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential for dissecting the causal roles of beta-catenin binding partners.
Description
GO:0008013 beta-catenin binding is a molecular function ontology term that describes the binding of a protein or other molecule to a catenin beta subunit, commonly known as beta-catenin. Beta-catenin is a dual-function protein that participates in cell adhesion and acts as a transcriptional co-activator in the Wnt signaling pathway. The binding of beta-catenin to various partners is a prerequisite for transmitting Wnt signals to the nucleus and for modulating gene expression programs that control proliferation, differentiation, and survival. Researchers study this term because the specificity and regulation of beta-catenin binding events determine normal development and are frequently corrupted in cancer and fibrotic diseases. Understanding the molecular details of beta-catenin binding provides a foundation for designing targeted therapies and for building accurate cell models using CRISPR gene editing.
beta-catenin binding At A Glance
| GO ID | GO:0008013 |
|---|---|
| GO term | beta-catenin binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a catenin beta subunit. |
| Major function | Mediates protein-protein interactions that enable Wnt signal transduction and transcriptional regulation. |
| Key binding partners | TCF/LEF transcription factors, FoxO1, ESE1, BAG2, SAMD4B, and condensate components. |
| Associated processes | Wnt signaling, cell proliferation, differentiation, fibrosis, and tumorigenesis. |
| Research relevance | Target for CRISPR knockout, point mutation, knock-in, and overexpression studies to dissect disease mechanisms. |
What Is GO:0008013?
In our own words, GO:0008013 beta-catenin binding refers to the molecular function of selectively interacting with a catenin beta subunit. This binding event is the physical basis for assembling protein complexes that either anchor beta-catenin at cell junctions or shuttle it into the nucleus to regulate transcription. The term does not describe a catalytic activity; rather, it captures a binding interaction that is essential for signal transduction and for the assembly of higher-order regulatory complexes.
Why Is beta-catenin binding Important in Cell Biology?
Beta-catenin binding is important because it governs the switch between beta-catenin's roles in cell adhesion and in nuclear transcription, and this switch is a decisive node in Wnt signaling. Aberrant beta-catenin binding contributes to cancer progression, as shown in cholangiocarcinoma where beta-catenin sustains YAP oncogenic activity, and in liver tumorigenesis driven by a beta-catenin-dependent enhancer. In chronic kidney disease, the balance between beta-catenin binding to TCF1 versus FoxO1 is associated with interstitial fibrosis in transplanted kidneys. Furthermore, beta-catenin cleavage and condensate formation add layers of regulation that fine-tune transcriptional output, making this binding function a rich area for therapeutic intervention.
• Beta-catenin binding is required for canonical Wnt signaling and target gene activation.
• It determines cell fate decisions in development and tissue homeostasis.
• Altered beta-catenin binding to TCF1 versus FoxO1 is linked to chronic interstitial fibrosis in kidney transplants.
• Beta-catenin binding to YAP sustains oncogenic activity in cholangiocarcinoma.
• The DLK1/DIO3 locus is upregulated by a beta-catenin-dependent enhancer, driving liver tumorigenesis.
• Beta-catenin cleavage enhances transcriptional activation, revealing post-translational control of binding.
• BAG2 releases SAMD4B upon arginine deficiency to promote tumor cell survival, involving beta-catenin-related complexes.
• Beta-catenin separation into biomolecular condensates is required for Wnt target gene activation.
• ESE1 was identified as a beta-catenin binding protein, expanding the repertoire of interactors.
• CRISPR models enable causal testing of beta-catenin binding partners in disease contexts.
What Happens During beta-catenin binding?
Wnt-induced stabilization and nuclear entry
In simple terms: When Wnt signals arrive, beta-catenin is protected from degradation and moves toward the nucleus.
In the absence of Wnt, beta-catenin is targeted for degradation, but Wnt signaling stabilizes it and allows it to accumulate and enter the nucleus. This stabilization is a prerequisite for beta-catenin binding to nuclear partners such as TCF/LEF transcription factors. The nuclear pool of beta-catenin is then available for binding events that activate target genes.
Binding to TCF/LEF and transcriptional activation
In simple terms: Beta-catenin binds to TCF/LEF proteins on DNA to turn on specific genes.
Once in the nucleus, beta-catenin binds to TCF/LEF family transcription factors and converts them from repressors into activators of Wnt target genes. This binding is essential for the transcriptional output of the pathway. In renal tubular cells, the choice between binding to TCF1 versus FoxO1 is associated with different outcomes, including chronic interstitial fibrosis in transplanted kidneys.
Alternative binding partners and context-dependent effects
In simple terms: Beta-catenin can bind to different proteins in different situations, leading to different results.
Beyond TCF/LEF, beta-catenin binds to proteins such as ESE1, which was identified as a beta-catenin binding protein. In cholangiocarcinoma, beta-catenin binding sustains and is required for YES-associated protein oncogenic activity. BAG2 releases SAMD4B upon sensing of arginine deficiency to promote tumor cell survival, implicating beta-catenin-associated complexes in metabolic stress responses.
Condensate formation and cleavage as regulatory layers
In simple terms: Beta-catenin can cluster into droplets and be cut by enzymes, which changes how it works.
Wnt target gene activation requires beta-catenin separation into biomolecular condensates, indicating that binding events are spatially organized. Beta-catenin cleavage enhances transcriptional activation, adding a proteolytic layer of control over its binding and function. These mechanisms fine-tune the intensity and duration of beta-catenin-dependent transcription.
Key Genes Involved in GO:0008013 beta-catenin binding
The following genes and proteins are experimentally validated participants in or regulators of beta-catenin binding (GO:0008013).
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTNNB1 | Encodes beta-catenin, the central protein in GO:0008013 | Core target for knockout, point mutation, and knock-in studies |
| TCF7 | TCF1 transcription factor that binds beta-catenin | Determines transcriptional outcomes in kidney fibrosis |
| FOXO1 | Alternative beta-catenin binding partner | Competes with TCF1 to influence fibrosis |
| YAP1 | Oncogenic co-activator sustained by beta-catenin | Required for cholangiocarcinoma growth |
| BAG2 | Chaperone that releases SAMD4B upon arginine deficiency | Links beta-catenin complexes to metabolic stress |
| SAMD4B | RNA-binding protein released by BAG2 | Implicated in tumor cell survival |
| ESE1 | Identified as a beta-catenin binding protein | Expands the interactome of beta-catenin |
| DLK1 | Upregulated by a beta-catenin-dependent enhancer | Drives liver tumorigenesis |
| DIO3 | Part of the DLK1/DIO3 locus | Upregulated in beta-catenin-driven liver tumors |
| LEF1 | TCF/LEF family transcription factor | Binds beta-catenin to activate Wnt targets |
| AXIN1 | Scaffold in the destruction complex | Regulates beta-catenin stability upstream of binding |
| APC | Destruction complex component | Controls beta-catenin levels and availability |
| GSK3B | Kinase that phosphorylates beta-catenin | Marks beta-catenin for degradation |
| CTNNBIP1 | Inhibitor of beta-catenin-TCF interaction | Modulates transcriptional output |
| CREBBP | Transcriptional co-activator recruited by beta-catenin | Enhances target gene activation |
| EP300 | Histone acetyltransferase in beta-catenin complexes | Regulates chromatin accessibility |
| TCF7L2 | TCF/LEF family member | Mediates beta-catenin-dependent transcription |
How Is beta-catenin binding Regulated?
Beta-catenin binding is regulated at multiple levels. The stability of beta-catenin is controlled by the destruction complex, which includes APC, AXIN1, and GSK3B, and Wnt signaling inhibits this complex to allow beta-catenin accumulation. Post-translational cleavage of beta-catenin enhances its transcriptional activation, providing a proteolytic switch. The separation of beta-catenin into biomolecular condensates is required for Wnt target gene activation, indicating that phase separation regulates binding competence. In kidney cells, the balance between beta-catenin binding to TCF1 versus FoxO1 is associated with fibrosis, suggesting that partner availability and competition regulate the functional outcome. Metabolic stress, such as arginine deficiency, can trigger BAG2-mediated release of SAMD4B, linking cellular metabolism to beta-catenin-associated complexes.
beta-catenin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CTNNB1 | Cholangiocarcinoma | Knockout and point mutation in cholangiocarcinoma cell lines |
| YAP1 | Cholangiocarcinoma | Knockdown or knockout to test beta-catenin dependence |
| TCF7 | Kidney fibrosis | Knock-in of binding-deficient mutants in renal tubular cells |
| FOXO1 | Kidney fibrosis | Overexpression and knockout to shift binding balance |
| DLK1 | Liver tumorigenesis | Knockout of beta-catenin-dependent enhancer |
Cancer
Beta-catenin binding is directly implicated in several cancers. In cholangiocarcinoma, beta-catenin sustains and is required for YES-associated protein oncogenic activity, making this binding event a potential therapeutic target. A beta-catenin-dependent enhancer upregulates the DLK1/DIO3 locus to drive cell proliferation and liver tumorigenesis. Beta-catenin cleavage enhances transcriptional activation, which may contribute to oncogenic gene expression programs. These findings highlight the importance of beta-catenin binding in tumor initiation and maintenance.
Kidney fibrosis
In transplanted kidneys, renal tubular cell binding of beta-catenin to TCF1 versus FoxO1 is associated with chronic interstitial fibrosis. This suggests that the choice of binding partner, rather than beta-catenin abundance alone, influences fibrotic outcomes. Targeting the specific beta-catenin interactions may offer a strategy to mitigate fibrosis.
Metabolic stress and tumor survival
BAG2 releases SAMD4B upon sensing of arginine deficiency to promote tumor cell survival, revealing a link between metabolic stress and beta-catenin-associated complexes. This pathway may allow tumor cells to adapt to nutrient-poor environments.
From beta-catenin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is CTNNB1 required for tumor growth? | CTNNB1 knockout cell lines and xenografts |
| Does beta-catenin binding to TCF1 versus FoxO1 determine fibrosis? | Point-mutation knock-in of binding-deficient CTNNB1 |
| Is condensate formation necessary for Wnt target activation? | Tagged knock-in of CTNNB1 with condensate-disrupting mutations |
| Does beta-catenin cleavage enhance transcription? | Knock-in of cleavage-resistant CTNNB1 |
| Does BAG2-SAMD4B interaction depend on beta-catenin? | Knockout of BAG2 and SAMD4B with rescue experiments |
| Can overexpression of ESE1 modulate beta-catenin targets? | Overexpression of ESE1 in reporter cell lines |
How to Study the beta-catenin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction with beta-catenin | Identifying novel binding partners like ESE1 |
| Mass spectrometry | Protein composition of beta-catenin complexes | Mapping context-dependent interactomes |
| Luciferase reporter assay | Transcriptional activity of beta-catenin | Testing cleavage and condensate effects |
| Fluorescence microscopy | Subcellular localization and condensates | Visualizing beta-catenin puncta |
| CRISPR knockout screening | Genes required for beta-catenin function | Discovering modulators of Wnt signaling |
| Proximity ligation assay | In situ protein-protein interactions | Detecting beta-catenin-TCF1 versus FoxO1 binding |
| RNA-seq | Transcriptional changes upon binding modulation | Measuring Wnt target gene expression |
| ChIP-seq | Beta-catenin occupancy on chromatin | Identifying enhancers like DLK1/DIO3 |
Co-immunoprecipitation and mass spectrometry
Co-immunoprecipitation followed by mass spectrometry is a standard approach to identify beta-catenin binding partners. This method was used to identify ESE1 as a beta-catenin binding protein. It can also reveal context-dependent interactions such as those with TCF1 or FoxO1.
Transcriptional reporter assays
Wnt-responsive luciferase reporters measure beta-catenin-dependent transcriptional activity. Such assays are used to test whether beta-catenin cleavage enhances transcriptional activation and whether condensate formation is required for target gene activation.
Imaging of condensates and nuclear localization
Fluorescence microscopy can visualize beta-catenin condensates and nuclear puncta. This approach demonstrated that Wnt target gene activation requires beta-catenin separation into biomolecular condensates. Live-cell imaging can track the dynamics of beta-catenin binding in real time.
CRISPR-based genetic screens
Genome-wide CRISPR screens can identify genes that regulate beta-catenin binding and downstream transcription. Such screens are valuable for uncovering novel modulators of Wnt signaling and for validating candidates in disease models.
How CRISPR Can Be Used to Study GO:0008013 beta-catenin binding
Knockout
CRISPR knockout of CTNNB1 or its binding partners is used to test requirement in disease models. For example, knockout of CTNNB1 in cholangiocarcinoma cells demonstrated that beta-catenin is required for YAP oncogenic activity. Knockout of BAG2 or SAMD4B can reveal their roles in tumor cell survival under arginine deficiency.
Point Mutation
Point mutations can disrupt specific binding interfaces without eliminating protein expression. This is useful to dissect whether beta-catenin binding to TCF1 versus FoxO1 determines fibrosis outcomes. Point mutations in the cleavage site can test the role of beta-catenin cleavage in transcriptional activation.
Knock-in
Knock-in of tagged or mutant beta-catenin allows tracking of condensate formation and binding dynamics. Tagged knock-in of CTNNB1 with condensate-disrupting mutations can test the requirement for phase separation in Wnt target activation. Knock-in of cleavage-resistant CTNNB1 can assess the impact on transcription.
Overexpression
Overexpression of beta-catenin or its binding partners can amplify signaling and reveal gain-of-function phenotypes. Overexpression of ESE1 was used to study its role as a beta-catenin binding protein. Overexpression of DLK1/DIO3 locus components can model liver tumorigenesis driven by beta-catenin-dependent enhancers.
How EDITGENE Supports beta-catenin binding Research
Researchers studying beta-catenin binding-related genes often need to determine whether a candidate gene is causally involved in Wnt signaling, fibrosis, or cancer. EDITGENE provides CRISPR-based cell models and screening services to accelerate this causal validation.
Contact EDITGENE today to design your custom CRISPR model for beta-catenin binding research.
Frequently Asked Questions About beta-catenin binding
What is GO:0008013 beta-catenin binding?
GO:0008013 is a molecular function term defined as binding to a catenin beta subunit, and it is central to Wnt signaling.
What genes are involved in beta-catenin binding?
Key genes include CTNNB1, TCF7, FOXO1, YAP1, BAG2, SAMD4B, ESE1, DLK1, and DIO3.
How does beta-catenin binding activate transcription?
Beta-catenin binds to TCF/LEF transcription factors in the nucleus and converts them into activators of Wnt target genes.
What is the role of beta-catenin binding in cancer?
Beta-catenin binding sustains YAP oncogenic activity in cholangiocarcinoma and drives liver tumorigenesis via a beta-catenin-dependent enhancer.
Can beta-catenin binding be studied with CRISPR?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are used to dissect beta-catenin binding in disease contexts.
What are biomolecular condensates in beta-catenin signaling?
Beta-catenin separates into biomolecular condensates, and this separation is required for Wnt target gene activation.
How is beta-catenin binding regulated?
It is regulated by beta-catenin stability, cleavage, condensate formation, and competition between binding partners such as TCF1 and FoxO1.
What diseases are linked to beta-catenin binding?
Diseases include cholangiocarcinoma, liver tumors, and chronic interstitial fibrosis in transplanted kidneys.
What methods are used to study beta-catenin binding?
Common methods include co-immunoprecipitation, mass spectrometry, luciferase reporters, fluorescence microscopy, and CRISPR screens.
Why is beta-catenin binding important for drug discovery?
Because specific binding events drive oncogenic and fibrotic programs, they represent actionable targets for therapeutic intervention.
Conclusion
GO:0008013 beta-catenin binding is a fundamental molecular function that connects Wnt signaling to transcriptional control, and its dysregulation is implicated in cancer and fibrosis. The diversity of binding partners, including TCF/LEF, FoxO1, ESE1, BAG2, and SAMD4B, underscores the context-dependent nature of this interaction. Advances in CRISPR modeling and screening now enable precise causal testing of these interactions, offering a path toward targeted therapies.
References
- 1. Akiyama T. 2000. Wnt/beta-catenin signaling.. Cytokine Growth Factor Rev 11(4):273-82 PMID: 10959075
- 2. Zhang Y et al.. 2022. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.. Gastroenterology 163(2):481-494 PMID: 35489428
- 3. Chen MY et al.. 2025. BAG2 releases SAMD4B upon sensing of arginine deficiency to promote tumor cell survival.. Mol Cell 85(13):2581-2596.e6 PMID: 40555234
- 4. Stewart RA et al.. 2024. Wnt target gene activation requires β-catenin separation into biomolecular condensates.. PLoS Biol 22(9):e3002368 PMID: 39316611
- 5. Yang Y et al.. 2021. Renal tubular cell binding of β-catenin to TCF1 versus FoxO1 is associated with chronic interstitial fibrosis in transplanted kidneys.. Am J Transplant 21(2):727-739 PMID: 32870598
- 6. Yang X et al.. 2016. Identification of ESE1 as a β-Catenin Binding Protein.. Anticancer Res 36(6):2697-703 PMID: 27272778
- 7. Sanceau J et al.. 2024. DLK1/DIO3 locus upregulation by a β-catenin-dependent enhancer drives cell proliferation and liver tumorigenesis.. Mol Ther 32(4):1125-1143 PMID: 38311851
- 8. Goretsky T et al.. 2018. Beta-catenin cleavage enhances transcriptional activation.. Sci Rep 8(1):671 PMID: 29330435
